TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06300177: A Randomized, Controlled, Double-blind, Double-simulated, Multicenter Phase III Clinical Study Evaluating D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 522 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,939,928

Rescue Site Savings

+$7,872,480

Unlock Full NCT06300177 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06300177 Rescue Dossier →